retatrutide parkinson clinical trial Lilly Prepares for FDA Filing Following Additional Phase 3 Data in Diabetes, CVD Today, we shared new data

Fast dispatch

How it works: GLP-1 and GIP suppress appetite, slow digestion, and enhance insulin secretion

This substantial weight loss not only improves overall health and quality of life but also contributes to better management of type 2 diabetes

DHvR has acted as a consultant and received honoraria from Boehringer Ingelheim and Eli Lilly, MSD, Novo Nordisk, and Sanofi and has received research operating funds from Boehringer Ingelheim-Eli Lilly Diabetes Alliance, MSD, AstraZeneca, and Novo Nordisk

Pharmaceutical GLP-1 analogs work by mimicking and extending the activity of this natural hormone - producing the appetite-suppressing and metabolic effects at sustained concentrations that the natural hormone, which is rapidly degraded by the enzyme DPP-4, can't maintain on its own

Effect of Drugs Used in Pharmacotherapy of Type 2 Diabetes on Bone Density and Risk of Bone Fractures